Nucleix is a biotechnology company based in Herzliya, Israel, specializing in the development of innovative diagnostic solutions. The company focuses on advancing cancer detection through its proprietary technologies, which leverage molecular biology and advanced analytics. Nucleix aims to improve patient outcomes by providing non-invasive testing methods that enhance early diagnosis and monitoring of various cancers. Their research is rooted in a commitment to transforming the landscape of cancer diagnostics and personalized medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

11 Patents

#35 in Herzliya

#573 in Israel

#51,761 in the World

Herzliya, Israel

Nucleix

Forward Citations = 14

8 inventors:

Danny Frumkin (10 out of 10 patents)

Adam Wasserstrom (10 out of 10 patents)

Revital Knirsh (5 out of 5 patents)

4. Orna Savin (2 out of 2 patents)

5. Mathias Ehrich (1 out of 38 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nucleix. Retrieved from https://idiyas.com/company/nucleix

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

6 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]